The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes
Open accessAbstract
An open-label, first-in-human phase 1/2 study is being conducted to evaluate the safety and efficacy of pancreatic endoderm cells (PECs) implanted in non-immunoprotective macroencapsulation devices for the treatment of type 1 diabetes. We report an analysis on 1 year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen. Implants were well tolerated with no teratoma formation or severe graft-related adverse events. After implantation, patients had increased fasting C-peptide levels and increased glucose-responsive C-peptide levels and developed mixed meal-stimulated C-peptide secretion. There were immunosuppression-related transient increases in circulating regulatory T cells, PD1 high T cells, and IL17A+CD4+ T cells. Explanted grafts contained cells with a mature β cell phenotype that were immunoreactive for insulin, islet amyloid polypeptide, and MAFA. These data, and associated findings (Shapiro et al., 2021), are the first reported evidence of meal-regulated insulin secretion by differentiated stem cells in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon graft removal, a majority of these graft-derived cells immunostained for the general endocrine marker chromogranin A (CHGA).”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the observed circulating C-peptide levels in these studies were too low to induce a measurable clinical benefit attributable to the transplanted cells, these clinical trials have demonstrated that facilitating host-derived vascularization into the graft promoted long-term endocrine cell survival and function in humans.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In other regions of the device, however, host fibroblasts were the predominant cell type, resulting in the deposition of fibrotic tissue rather than host-derived vasculature.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the observed circulating C-peptide levels in these studies were too low to induce a measurable clinical benefit attributable to the transplanted cells, these clinical trials have demonstrated that facilitating host-derived vascularization into the graft promoted long-term endocrine cell survival and function in humans.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As intended, the porous design promoted the growth of host-derived blood vessels inside the device, and this phenomenon was more prominent in regions containing the graft-derived cells.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ViaCyte clinical trial, the explanted grafts after months in vivo were observed to be highly heterogenous between patients since the cells were transplanted as pancreatic progenitors and allowed to finish differentiating in vivo.33,35”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, while there were regions of C-peptide positive β-like cells, a majority of these endocrine cells stained for the α cell marker glucagon. Ductal cells and rare acinar cells were also observed.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the transplanted PEC-Encap product was well tolerated with few adverse effects, the trial was halted due to insufficient functional product engraftment.33”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“these macroencapsulation devices can also promote fibrosis around the implant, further preventing nutrient diffusion.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, these studies did not detect any serious safety concerns related to the transplanted cells, such as tumor formation.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“An ongoing clinical trial was started in 2017 at seven sites to test this device (clinicaltrials.gov: NCT03163511), and the first round of results have recently been published.33,35”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“While some endocrine cells were observed, fibrosis around the capsule resulted in graft loss, and no insulin secretion from the device was detected.33,34”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“They demonstrated glucose responsive C-peptide production 6-9 months post-transplant as the grafted cells matured from pancreatic progenitors into pancreatic endocrine cells.”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationThe Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells
D’Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O., Agulnick, A. D., Smart, N. G., Moorman, M. A., KROON, E. J., Carpenter, M. K., & Baetge, E. E. (2006) · Nature Biotechnology · doi:10.1038/nbt1259 · Cited by 1,913
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843
Efficient differentiation of human embryonic stem cells to definitive endoderm
D'Amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., & Baetge, E. E. (2005) · Nature Biotechnology · doi:10.1038/nbt1163 · Cited by 1,730
Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
Self-citationRituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Cited by
Sorted by citations
Items 301–341 of 341
Quality control programmes for induced pluripotent stem cell-derived medicinal products
Melnikova, E. V., Анатольевна, Р. О., Семенова, И. С., & Меркулов, В. А. (2025) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2025-25-2-127-140
Advances in Islet Function Replacing Strategies After Total Pancreatectomy
Peng, S., Zhao, B., Yi, X., Li, X., Zhang, J., Wang, J., & Li, R. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.012
Risk of Allosensitization for Islet Recipients and Impact on Access To Renal Transplant
Czarnecka, Z., & Shapiro, A. M. J. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00484-6
Stem cell-derived islets — significant progress amidst ongoing challenges for type 1 diabetes
Dong, L., Cao, X., Mi, C., Fu, H., & Liu, H. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100149
Petrauskas, V., Strupas, K., & Gulla, A. (2025) · Visceral Medicine · doi:10.1159/000547931
Regenerative Medicine and Endocrinology: Advanced Cell Therapies for Diabetes
Ghezelayagh, Z., Tahamtani, Y., Valizadeh, M., & Aghayan, H. R. (2025) · Springer eBooks · doi:10.1007/978-981-95-2286-6_4
Lü, J., Kim, H., Zhu, J., Martin, C., Zhang, J., Polavarapu, V., Lacko, L. A., Ariyachet, C., Dattoli, A. A., Liu, T., et al. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102708
Regulation of insulin expression and release in gene and cell therapy of insulin-deficient diabetes
Xie, L., Lu, W., Yu, J., Zhang, Y., Gao, H., Xie, C., Tian, Y., Liu, M., & Wang, G. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf231
Cell encapsulation: a living drug delivery approach
Zhang, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23521-4.00007-2
miR-302 regulates pancreatic progenitor pool and pancreatic size
Yang, Z., Snider, C. G., & Parchem, R. J. (2025) · Biology Open · doi:10.1242/bio.062353
Sakuma, K., Tsubooka-Yamazoe, N., Hashimoto, K., Sakai, N., Asano, S., Watanabe-Matsumoto, S., Watanabe, T., Saito, B., Matsumoto, H., Ueno, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22603246
Bai, X., Chen, H., Odorico, J. S., Chamberlain, C. S., Molakandov, K., Dargaville, T. R., Revel, M., & Tuch, B. E. (2026) · Diabetology · doi:10.3390/diabetology7010005
Bioengineering of vascular macrodevices for transplantation of insulin-producing cells
Karami, M., Halvaei, M., Royaei, R., Tahamtani, Y., & Ashtiani, M. K. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.11.020
Zheng, C., Lu, S., Qiang, D., Xu, J., & Xu, Y. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70120
Stem cell transplantation in immuno-hematologic and infectious diseases
Mwita, R. P., & Özdemır, Ö. (2026) · World Journal of Transplantation · doi:10.5500/wjt.v16.i1.114592
Maloney, K., Azar, W. S., McKenney, J., Upasani, P., & Gallicano, I. (2025) · Harvard Medical Student Review · doi:10.65539/xdtar040
Cell Therapy for Type 1 Diabetes Mellitus
Ghoneim, M. A., Refaie, A. F., & Gabr, M. M. (2026) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-032-12705-1_6
Xu, J., Shen, X., Gu, Y., Lewis, D. F., Zoorob, D. G., & Wang, Y. (2026) · PROTEOMICS · doi:10.1002/pmic.70120
Metabolic Maturation and Clinical Translation of Stem Cell-Derived β-Cells in Diabetes Therapy
Serdah, R., & Gallicchio, V. S. (2026) · Journal of Regenerative Medicine and Biology Research · doi:10.46889/jrmbr.2026.7108
Diané, A., Mu-u-min, R., Al-Shukri, N. A., Nour‐Eldine, W., & Al-Siddiqi, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1795738 · Cited by 1
Emerging therapies for type 1 diabetes: Immunotherapy and gene editing advances
Zhao, M., & Yao, Z. (2026) · Journal of International Medical Research · doi:10.1177/03000605261440833
Evaluating iPSC-based interventions for diabetes: a systematic review and meta-analysis
Tan, V. M., Anh, K. T. L., Hiền, L. T., Trang, V. T. T., Nguyet, P. M., Linh, D. P., Yen, T. T. H., & Quan, V. D. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02168-2
Rojas, A. C., Brassard, J., Billaud, M., Lemaire, F., Chen, R., Tian, J., Orimi, H. E., Paraskevas, S., & Hoesli, C. A. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102407
What Is the Current State of Stem Cell Therapy in Diabetes?
Bakinowska, E., Biniek, W. J., Kiełbowski, K., Dyrka, K., Szewczyk, K., Ostałowska, H., Leciej, Z., & Pawlik, A. (2026) · Cells · doi:10.3390/cells15100907
Microscale strategies in engineering the pancreas: Toward clinical translation
Billaud, M., Campbell, B. E., Zhu, X., Ling, S. D., Movasat, H., Li, C., Prezelj, D., Vdovenko, D., Shakiba, N., Hoesli, C. A., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115919
Guttikonda, S., Machur, J. C., Matha, C. P., Mathew, R. R., & Thotakura, T. (2026) · Cureus · doi:10.7759/cureus.111930
Kawaguchi, Y., Nakayama, M., Kanetaka, K., Higashi, M., Maruya, Y., Kobayashi, S., Matsumura, M., Naka, T., & Eguchi, S. (2026) · Cell Transplantation · doi:10.1177/09636897261466845
Huang, X., chen, Q., & Lü, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1856373
Ebrahim, N., Kondratyev, N. V., Artyuhov, A., Timofeev, A., Stepanenko, A., & Dashinimaev, E. B. (2026) · Research Square · doi:10.21203/rs.3.rs-9705786/v1
Stem Cell–Derived Islet Therapy for Type 1 Diabetes
Barsby, T., Balboa, D., & Otonkoski, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00025-1
Advanced therapy medicinal products
Aabling, R. R., Revenfeld, A. L., & Rusan, M. (2026) · Ugeskrift for Læger · doi:10.61409/v12251027
Stem cell strategies for cell replacement therapy in endocrine diseases
Mi, C., Xie, C., Tang, J., Gao, Y., Zhang, J., Yang, Y., Tan, G., Zheng, C., & Liu, H. (2026) · Cell Transplantation · doi:10.1177/09636897261486242
The comparative cell physiology of stem cell-derived and primary human β cells
Maghera, J., Chu, C. M. J., Schaaf, C., Bruin, J. E., Johnson, J. D., Lynn, F. C., & MacDonald, P. E. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01295-0 · Cited by 1
Qiao, G., Adejobi, O. I., Li, X., Yang, Y., He, X., Li, L., Zhou, Y., Li, J., Li, H., Zhang, F., et al. (2026) · Biomolecules · doi:10.3390/biom16091338
Engineering an Implantable Bioartificial Pancreas to Balance Transport, Containment, and Retrieval
Shi, H., Li, Y., He, C., & Sun, B. (2026) · Artificial Organs · doi:10.1111/aor.70254
Odorico, J. S., Citro, A., de Koning, E. J. P., Kay, T., Latres, E., Millman, J. R., Nostro, M. C., Piemonti, L., Rickels, M. R., Russ, H. A., et al. (2026) · Transplantation · doi:10.1097/tp.0000000000005783
Chen, L., Hu, X., Zheng, C., Huang, Q., Xu, J., You, X., & Wang, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1981945
Citro, A., & Piemonti, L. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1943061
Oh, S.-Y., Park, Y. S., Choi, B. H., Kim, H. S., Jung, S.-C., & Jo, I. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109133
Metadata
- Authors
- Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., & Kieffer, T. J.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Kieffer, Timothy J.
- ORCID
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 28
- Issue
- 12
- Pages
- 2047-2061.e5
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- OpenAlex
- W3214753991
- Cited by
- 342
- References
- 55
- Citations by year
- 2026: 46 · 2025: 75 · 2024: 75 · 2023: 66 · 2022: 76 · 2021: 3
- FWCI
- 51.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell stem cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Stem Cell Network
- California Institute for Regenerative Medicine
- Juvenile Diabetes Research Foundation United States of America
- BC Children’s Hospital
- Juvenile Diabetes Research Foundation Canada
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- type 1 diabetes, pluripotent stem cells, cell therapy, macroencapsulation, C-peptide secretion, glucose-dependent insulin secretion, beta cell differentiation, regulatory T cells, immunosuppression, graft safety, amylin, MafA
- MeSH terms
- C-Peptide, Cell Differentiation, Diabetes Mellitus, Type 1, Endoderm, Glucose, Humans, Insulin, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
